Loading…
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $607M | $-41M | $-226M | $-191M | -17.8% | -14.9% | 324.0% |
| 2024 | $713M | $135M | $-53M | $-208M | -3.9% | -17.4% | -71.8% |
| 2023 | $863M | $-66M | $-189M | $-44M | -13.6% | -14.0% | -42.5% |
| 2022 | $1.0B | $-271M | $-328M | $-120M | -21.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1,004.20 | 863.50 | 713.14 | 606.88 |
| Operating Revenue | - | 1,004.20 | 863.50 | 713.14 | 606.88 |
| Cost Of Revenue | - | 715.98 | 545.37 | 494.63 | 400.94 |
| Gross Profit | - | 288.22 | 318.13 | 218.51 | 205.94 |
| Operating Expense | - | 534.34 | 476.18 | 492.07 | 424.92 |
| Research And Development | - | 73.89 | 89.59 | 105.21 | 124.03 |
| Selling General And Administration | - | 372.67 | 300.56 | 304.22 | 223 |
| Total Expenses | - | 1,250.32 | 1,021.55 | 986.70 | 825.86 |
| Total Operating Income As Reported | - | -226.25 | -157.02 | -152.06 | -117.41 |
| EBITDA | - | -270.81 | -65.52 | 135.28 | -41.28 |
| Normalized EBITDA | - | -291.33 | -65.77 | 39.95 | -142.42 |
| EBIT | - | -379.46 | -170.81 | 37.10 | -132.90 |
| Interest Income | - | 1.98 | 3.98 | 8.43 | 14.81 |
| Interest Expense | - | 12.06 | 13.51 | 47.46 | 108.46 |
| Net Interest Income | - | -10.07 | -9.52 | -39.04 | -93.65 |
| Other Non Operating Income Expenses | - | -155.84 | -16.99 | 206.90 | -29.88 |
| Other Income Expense | - | -135.32 | -16.74 | 302.24 | 71.27 |
| Interest Income Non Operating | - | 1.98 | 3.98 | 8.43 | 14.81 |
| Interest Expense Non Operating | - | 12.06 | 13.51 | 47.46 | 108.46 |
| Net Non Operating Interest Income Expense | - | -10.07 | -9.52 | -39.04 | -93.65 |
| Pretax Income | - | -391.52 | -184.32 | -10.36 | -241.36 |
| Tax Provision | - | -63.50 | 4.44 | 42.84 | -15.71 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 3.32 | 0.05 | 20.02 | 6.58 |
| Net Income Continuous Operations | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income From Continuing And Discontinued Operation | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income From Continuing Operation Net Minority Interest | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income Common Stockholders | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Net Income Including Noncontrolling Interests | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Normalized Income | - | -345.60 | -189.06 | -128.54 | -320.24 |
| Diluted NI Availto Com Stockholders | - | -328.40 | -188.86 | -53.22 | -225.68 |
| Basic Average Shares | - | 719.06 | 751.72 | 694.02 | 751.13 |
| Diluted Average Shares | - | 719.06 | 751.72 | 694.02 | 751.13 |
| Reconciled Depreciation | - | 108.66 | 105.30 | 98.18 | 91.63 |
| Reconciled Cost Of Revenue | - | 695.11 | 526.10 | 479.09 | 387.20 |
| Total Unusual Items | - | 20.52 | 0.26 | 95.33 | 101.15 |
| Total Unusual Items Excluding Goodwill | - | 20.52 | 0.26 | 95.33 | 101.15 |
| Earnings From Equity Interest Net Of Tax | - | -0.38 | -0.11 | -0.02 | -0.03 |
| Special Income Charges | - | 19.87 | 1.04 | 121.49 | 101.58 |
| Write Off | 0 | - | - | - | - |
| Restructuring And Mergern Acquisition | - | -1.31 | -1.04 | 0 | 0 |
| Gain On Sale Of Security | - | 0.65 | -0.78 | -26.16 | -0.43 |
| Depreciation Amortization Depletion Income Statement | - | 87.78 | 86.03 | 82.63 | 77.89 |
| Depreciation And Amortization In Income Statement | - | 87.78 | 86.03 | 82.63 | 77.89 |
| Gain On Sale Of Ppe | - | 18.56 | 0 | 121.49 | 101.58 |
| Amortization | - | 87.78 | 86.03 | 82.63 | 77.89 |
| Amortization Of Intangibles Income Statement | - | 87.78 | 86.03 | 82.63 | 77.89 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OPKO Health, Inc.this co. | OPK | $1.1B | -4.88 | 0.87 | -17.8% | -27.38 |
| Absci Corporation | ABSI | $1.1B | -9.94 | 6.04 | -60.8% | -10.95 |
| Aktis Oncology, Inc. | AKTS | $1.1B | -17.25 | -7.52 | 43.6% | -14.83 |
| MannKind Corporation | MNKD | $1.1B | 185.49 | -21.31 | -11.5% | 26.79 |
| Savara Inc. | SVRA | $1.1B | -9.14 | 5.35 |
| - |
| - |
| - |
| - |
| - |
| -58.5% |
| -8.83 |
| Omada Health, Inc. | OMDA | $1.1B | -84.72 | 4.71 | -5.6% | -181.05 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.1B | 1916.51 | 77.56 | 4.0% | 28.56 |
| Collegium Pharmaceutical, Inc. | COLL | $1.1B | 16.86 | 3.51 | 20.8% | 4.10 |
| CONMED Corporation | CNMD | $1.1B | 22.48 | 1.02 | 4.6% | 10.49 |
| Peer Median | - | 3.86 | 4.11 | -0.8% | -2.36 | |